Biotechnology

Filter

Current filters:

None

Popular Filters

1980 to 2004 of 2471 results

Clinical trials due an overhaul to conquer the Pharma "Valley of Death"

30-09-2012

Costs associated with drug development have risen from around $138 million in 1975 to over $1 billion…

BiotechnologyFinancialGlobalPharmaceuticalResearch

Australian government proposes "tough new standards" for Innovation Patents

27-09-2012

Australia's federal government said in media release this week that it is "considering tough new standards…

Asia-PacificBiotechnologyPatentsPharmaceuticalPolitics

Biocitech life sciences park highlights biotechnology and enterprise creation in north east Paris area

27-09-2012

Biocitech, the Paris, France, life sciences technology park, said yesterday that it is giving its support…

BiocitechBiotechnologyEuropeResearch

Uptake of biosimilars will see Remicade and Humira sales decline in 2017

26-09-2012

The TNF-alpha inhibitors infliximab (Janssen Biotech/Merck/Mitsubishi Tanabe's Remicade) and adalimumab…

BiotechnologyGastro-intestinalsGenericsGlobalHumiraMarkets & MarketingRemicade

Roche buys rights to preclinical stage oncology program from Galaxy Biotech

26-09-2012

Switzerland-based Roche (SIX: ROG), the world's largest cancer drug company, has licensed exclusive worldwide…

BiotechnologyGalaxy BiotechLicensingOncologyPharmaceuticalRoche

Russia's Maxwell Biotech Venture Fund invests in Osteros Biomedica

26-09-2012

Earlier this month, the investment committee of Maxwell Biotech Venture Fund (MBVF), founded with the…

BiotechnologyMaxwell BiotechMBC PharmaMBC-11Mergers & AcquisitionsOncologyOsteros BiomedicaResearch

Sanofi to cut 900 French research posts, a lot fewer than had been feared

25-09-2012

French drug major Sanofi (Euronext: SAN) yesterday fleshed out on its plans for changes in its research…

BiotechnologyEuropeManagementPharmaceuticalResearchSanofi

Pfizer and Roche hope to score with ESMO presentations, notes GlobalData

25-09-2012

The European Society for Medical Oncology (ESMO) will kick off its 2012 annual meeting on Friday, September…

BiotechnologyHerceptinOncologyPfizerPharmaceuticalResearchRocheXalkori

Peregrine Pharma plummets after revealing "discrepancies" in one bavituximab trial

25-09-2012

Shares of US drugmaker Peregrine Pharmaceuticals (Nasdaq: PPHM) went into free-fall in pre-market trading…

bavituximabBiotechnologyOncologyPeregrine PharmaceuticalsPharmaceuticalResearch

Astex Pharma shares down after company drops amuvatinib development

25-09-2012

US drug developer Astex Pharmaceuticals (Nasdaq: ASTX) saw its shares fall 8.1% to $3.05 by close last…

amuvatinibAstex PharmaceuticalsBiotechnologyLicensingOncologyPharmaceuticalResearch

Denosumab reduces burden of giant-cell tumor of the bone

25-09-2012

Treatment with denosumab, a drug from Amgen (Nasdaq: AMGN), the world's largest biotech firm which markets…

AmgenBiotechnologydenosumabOncologyProliaResearchXgeva

MorphoSys rises on positive mid-stage results for RA compound MOR103

24-09-2012

German biotechnology firm MorphoSys (FSE: MOR) saw its shares rise 15.1% to an 11-year high of 22.30…

BiotechnologyLicensingMOR103MorphoSysResearch

Amgen's Prolia gets FDA nod for men with osteoporosis

24-09-2012

The US Food and Drug Administration last week approved a new indication for world biotech leader Amgen's…

AmgenAnti-Arthritics/RheumaticsBiotechnologyMen's HealthNorth AmericaProliaRegulation

Addressing the boardroom gender gap in life sciences industry

23-09-2012

Nick Stephens, executive chairman of RSA, a global life sciences executive search and interim management…

BiotechnologyEuropeManagementPharmaceutical

Positive trial results for Biogen Idec's MS drug BG-12

21-09-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) says that data from the Phase III DEFINE and CONFIRM studies…

BG-12Biogen IdecBiotechnologydimethyl fumarateNeurologicalResearch

Biotech industry R&D spending jumps 5% in 2011, BDO Study Finds; Exec salaries

20-09-2012

Research and development expenditures in the biotechnology industry grew 5% in 2011, bouncing back after…

BiotechnologyFinancialManagementNorth AmericaResearch

Lutathera first MNM theragnostic drug, enters Ph III in cancer patients with midgut carcinoid

20-09-2012

France-based Advanced Accelerator Applications (AAA), a privately-owned player in molecular nuclear medicine…

Advanced Accelerator ApplicationsBiotechnologyLutatheraOncologyResearchSandostatin

Rainbow Biosciences in talks to license NASA bioreactor technology

20-09-2012

Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp (OTCBB: RBCC).says that it has engaged…

BiotechnologyLicensingRainbow BiosciencesRegenetech

1980 to 2004 of 2471 results

Back to top